Rapid publication
c-erbB-2 oncogene expression in hepatocellular carcinoma and cholangiocarcinoma

https://doi.org/10.1016/0168-8278(92)90186-SGet rights and content

Abstract

The c-erbB-2 proto-oncogene encodes a transmembrane protein which is homologous to the epidermal growth factor receptor. This protein can be localized immunohistochemically in formalin-fixed paraffin-embedded material using a monoclonal antibody NCL-CB11; positive membrane staining correlates with gene amplification and protein overexpression in breast cancer. Using this technique we have shown that only 226 (8%) of hepatocellular carcinomas, 010 (0%) of cholangiocarcinomas and 02 (0%) hepatoblastomas overexpressed c-erbB-2 as evidenced by membrane staining. Moreover c-erbB-2 mRNA was not detected in seven hepatocellular carcinomas examined by Northern blot analysis. c-erbB-2 overexpression is, therefore, unlikely to be contributing to the malignant phenotype in hepatocellular carcinoma and cholangiocarcinoma.

References (10)

  • WJ Muller et al.

    Single step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene

    Cell

    (1988)
  • T Yamamoto et al.

    Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor

    Nature

    (1986)
  • C Lovekin et al.

    c-erbB-2 oncogene expression in breast cancer: relationships and prognostic significance

    J Pathol

    (1989)
  • N Voravud et al.

    Oncogene expression in cholangiocarcinoma and in normal hepatic development

    Hum Pathol

    (1990)
  • IP Corbett et al.

    NCL-CB11, a new monoclonal antibody recognising the internal domain of the c-erbB-2 oncogene protein effective for use on formalin fixed paraffin embedded tissue

    J Pathol

    (1990)
There are more references available in the full text version of this article.

Cited by (49)

  • Cholangiocarcinoma

    2017, Zakim and Boyer's Hepatology: A Textbook of Liver Disease
  • Cholangiocarcinoma

    2012, Zakim and Boyer's Hepatology
  • Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma

    2011, HPB
    Citation Excerpt :

    It also suggests that, although ErbB2 was gained at a DNA level in all cases in this study, there is a further level of control of expression at a transcriptomic or proteomic level. Our findings are supported by the widely variable data from other studies of ErbB2 in CC, in which gene amplification is reported in 2–100% of cases41–45 and protein overexpression varies from none to 80%.41–58 Other CGH studies using metaphase chromosome CGH have identified CN gain in the same region in only 0–50% of cases (Fig. 4).

  • Gene amplification and protein overexpression of HER-2/neu in human extrahepatic cholangiocarcinoma as detected by chromogenic in situ hybridization and immunohistochemistry: Its prognostic implication in node-positive patients

    2007, Annals of Oncology
    Citation Excerpt :

    While 27%–82% of tumors were found to express HER-2/neu in CC of Thai, English, Taiwanese. American, and Japanese origin [18–22], Collier et al. [17] were unable to detect the expression of membranous HER-2/neu in 10 cases of human CCs of European Caucasian origin by immunohistochemistry. In Japanese study [22], it was indicated that positive immunohistochemical (IHC) staining of HER-2/neu in CC correlated with a shorter survival.

  • Cholangiocarcinoma

    2006, Zakim and Boyer's Hepatology
View all citing articles on Scopus
View full text